Tarabra, Elena, Pelengaris, Stella and Khan, Michael. (2012) A simple matter of life and death : the trials of postnatal beta-cell mass regulation. International Journal of Endocrinology, Vol.2012 . Article no. 516718. ISSN 1687-8337

Preview

PDF WRAP_Khan_516718.pdf - Published Version - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader Download (877Kb)

Abstract

Pancreatic beta-cells, which secrete the hormone insulin, are the key arbiters of glucose homeostasis. Defective beta-cell numbers and/or function underlie essentially all major forms of diabetes and must be restored if diabetes is to be cured. Thus, the identification of the molecular regulators of beta-cell mass and a better understanding of the processes of beta-cell differentiation and proliferation may provide further insight for the development of new therapeutic targets for diabetes. This review will focus on the principal hormones and nutrients, as well as downstream signalling pathways regulating beta-cell mass in the adult. Furthermore, we will also address more recently appreciated regulators of beta-cell mass, such as microRNAs.

Item Type:	Journal Article
Subjects:	Q Science > QP Physiology
Divisions:	Faculty of Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH):	Pancreatic beta cells -- Synthesis -- Regulation
Journal or Publication Title:	International Journal of Endocrinology
Publisher:	Hindawi Publishing Corporation
ISSN:	1687-8337
Date:	2012
Volume:	Vol.2012
Page Range:	Article no. 516718
Identification Number:	10.1155/2012/516718
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Open Access
References:	[1] Y. Dor andD. A.Melton, “Howimportant are adult stemcells for tissue maintenance?” Cell Cycle, vol. 3, no. 9, pp. 1104– 1106, 2004. [2] C. J. Rhodes, “Type 2 diabetes—a matter of β-cell life and death?” Science, vol. 307, no. 5708, pp. 380–384, 2005. [3] S. Bonner-Weir, “Islet growth and development in the adult,” Journal of Molecular Endocrinology, vol. 24, no. 3, pp. 297– 302, 2000. [4] B. Duvilli´e, C. Currie, T. Chrones et al., “Increased islet cell proliferation, decreased apoptosis, and greater vascularization leading to β-cell hyperplasia in mutant mice lacking insulin,” Endocrinology, vol. 143, no. 4, pp. 1530–1537, 2002. [5] E. Bernal-Mizrachi, W. Wen, S. Stahlhut, C. M. Welling, and M. A. Permutt, “Islet β cell expression of constitutively active Akt1/PKBα induces striking hypertrophy, hyperplasia, and hyperinsulinemia,” Journal of Clinical Investigation, vol. 108, no. 11, pp. 1631–1638, 2001. [6] A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, “β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes,” Diabetes, vol. 52, no. 1, pp. 102–110, 2003. [7] S. Georgia and A. Bhushan, “β cell replication is the primary mechanism for maintaining postnatal β cell mass,” Journal of Clinical Investigation, vol. 114, no. 7, pp. 963–968, 2004. [8] D. Mathis, L. Vence, and C. Benoist, “β-cell death during progression to diabetes,” Nature, vol. 414, no. 6865, pp. 792– 798, 2001. [9] A. R. Saltiel and C. R. Kahn, “Insulin signalling and the regulation of glucose and lipid metabolism,” Nature, vol. 414, no. 6865, pp. 799–806, 2001. [10] I. Swenne and A. Andersson, “Effect of genetic background on the capacity for islet cell replication in mice,” Diabetologia, vol. 27, no. 4, pp. 464–467, 1984. [11] A. M. Ackermann and M. Gannon, “Molecular regulation of pancreatic β-cell mass development, maintenance, and expansion,” Journal of Molecular Endocrinology, vol. 38, no. 1-2, pp. 193–206, 2007. [12] T. Okada, W. L. Chong, J. Hu et al., “Insulin receptors in β- cells are critical for islet compensatory growth response to insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 8977–8982, 2007. [13] Y. Terauchi, I. Takamoto, N. Kubota et al., “Glucokinase and IRS-2 are required for compensatory β cell hyperplasia in response to high-fat diet-induced insulin resistance,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 246–257, 2007. [14] S. L. Fernandez-Valverde, R. J. Taft, and J. S. Mattick, “MicroRNAs in β-cell biology, insulin resistance, diabetes and its complications,” Diabetes, vol. 60, no. 7, pp. 1825–1831, 2011. [15] M. N. Poy, J. Hausser, M. Trajkovski et al., “miR-375 maintains normal pancreatic α- and β-cellmass,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 14, pp. 5813–5818, 2009. [16] Y. Li, X. Xu, Y. Liang et al., “miR-375 enhances palmitateinduced lipoapoptosis in insulin-secreting NIT-1 cells by repressing myotrophin (V1) protein expression,” International Journal of Clinical and Experimental Pathology, vol. 3, no. 3, pp. 254–264, 2010. [17] A. E. Ouaamari, N. Baroukh, G. A. Martens, P. Lebrun, D. Pipeleers, and E. Van Obberghen, “MiR-375 targets 3�lphosphoinositide- dependent protein Kinase-1 and regulates glucose-induced biological responses in pancreatic β-Cells,” Diabetes, vol. 57, no. 10, pp. 2708–2717, 2008. [18] H. Q. Xia, Y. Pan, J. Peng, and G. X. Lu, “Over-expression of miR375 reduces glucose-induced insulin secretion in Nit- 1 cells,” Molecular Biology Reports, vol. 38, no. 5, pp. 3061– 3665, 2011. [19] M. I. McCarthy, “Genomics, type 2 diabetes, and obesity,” The New England Journal of Medicine, vol. 363, no. 24, pp. 2339–2350, 2010. [20] World Health Organization, “Diabetes Fact Sheet no. 312,” 2011, http://www.who.int/mediacentre/factsheets/fs312en/ index.html. [21] J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. [22] J. Levy, A. B. Atkinson, P. M. Bell, D. R.McCance, and D. R. Hadden, “Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the belfast diet study,” Diabetic Medicine, vol. 15, no. 4, pp. 290–296, 1998. [23] R. Turner, “Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33),” The Lancet, vol. 352, no. 9131, pp. 837–853, 1998. [24] R. Turner, “Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34),” The Lancet, vol. 352, no. 9131, pp. 854–865, 1998. [25] H. Shamoon, H. Duffy, N. Fleischer et al., “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. [26] B. Richter, E. Bandeira-Echtler, K. Bergerhoff, C. Clar, and S. H. Ebrahim, “Rosiglitazone for type 2 diabetes mellitus,” Cochrane Database of Systematic Reviews (Online), no. 3, article CD006063, 2007. [27] Y. Dor, J. Brown, O. I. Martinez, and D. A. Melton, “Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation,” Nature, vol. 429, no. 6987, pp. 41– 46, 2004. [28] E. Montanya, V. Nacher, M. Biarnes, and J. Soler, “Linear correlation between β-cell mass and body weight throughout the lifespan in Lewis rats. Role of β-cell hyperplasia and hypertrophy,” Diabetes, vol. 49, no. 8, pp. 1341–1346, 2000. [29] J. H. Nielsen, E. D. Galsgaard, A. Møldrup et al., “Regulation of β-cell mass by hormones and growth factors,” Diabetes, vol. 50, no. 1, supplement, pp. S25–S29, 2001. [30] A. E. Butler, J. Janson, W. C. Soeller, and P. C. Butler, “Increased β-cell apoptosis prevents adaptive increase in β- cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid,” Diabetes, vol. 52, no. 9, pp. 2304–2314, 2003. [31] J. J. Gagliardino, H. Del Zotto, L. Massa, L. E. Flores, and M. I. Borelli, “Pancreatic duodenal homeobox-1 and islet neogenesis-associated protein: a possible combined marker of activateable pancreatic cell precursors,” Journal of Endocrinology, vol. 177, no. 2, pp. 249–259, 2003. [32] G. M. Steil, N. Trivedi, J. C. Jonas et al., “Adaptation of β- cell mass to substrate oversupply: enhanced function with normal gene expression,” American Journal of Physiology, vol. 280, no. 5, pp. E788–E796, 2001. [33] C. Bernard, M. F. Berthault, C. Saulnier, and A. Ktorza, “Neogenesis vs. apoptosis as main components of pancreatic β cell mass changes in glucose-infused normal and mildly diabetic adult rats,” FASEB Journal, vol. 13, no. 10, pp. 1195– 1205, 1999. [34] C. Bernard, C. Thibault, M. F. Berthault et al., “Pancreatic β-cell regeneration after 48-h glucose infusion in mildly diabetic rats is not correlated with functional improvement,” Diabetes, vol. 47, no. 7, pp. 1058–1065, 1998. [35] S. Bonner-Weir, D. Deery, J. L. Leahy, and G. C. Weir, “Compensatory growth of pancreatic β-cells in adult rats after short-term glucose infusion,” Diabetes, vol. 38, no. 1, pp. 49–53, 1989. [36] M. Paris, C. Bernard-Kargar, M. F. Berthault, L. Bouwens, and A. Ktorza, “Specific and combined effects of insulin and glucose on functional pancreatic β-cell mass in vivo in adult rats,” Endocrinology, vol. 144, no. 6, pp. 2717–2727, 2003. [37] D. R. Laybutt, M. Glandt, G. Xu et al., “Critical reduction β- cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes,” The Journal of Biological Chemistry, vol. 278, no. 5, pp. 2997–3005, 2003. [38] I. Swenne, “The role of glucose on the in vitro regulation of cell cycle kinetics and proliferation of fetal pancreatic Bcells,” Diabetes, vol. 31, no. 9, pp. 754–760, 1982. [39] B.G. Topp, M. D. McArthur, and D. T. Finegood, “Metabolic adaptations to chronic glucose infusion in rats,” Diabetologia, vol. 47, no. 9, pp. 1602–1610, 2004. [40] S. Porat, N. Weinberg-Corem, S. Tornovsky-Babaey et al., “Control of pancreatic β cell regeneration by glucose metabolism,” Cell Metabolism, vol. 13, no. 4, pp. 440–449, 2011. [41] A. Hoorens, M. van de Casteele, G. Kl¨oppel, and D. Pipeleers, “Glucose promotes survival of rat pancreatic β cells by activating synthesis of proteins which suppress a constitutive apoptotic program,” Journal of Clinical Investigation, vol. 98, no. 7, pp. 1568–1574, 1996. [42] J. C. Jonas, A. Sharma, W. Hasenkamp et al., “Chronic hyperglycemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes,” The Journal of Biological Chemistry, vol. 274, no. 20, pp. 14112–14121, 1999. [43] V. Grill and A. Bj¨orklund, “Overstimulation and β-cell function,” Diabetes, vol. 50, supplement 1, pp. S122–S124, 2001. [44] K. Maedler, P. Sergeev, F. Ris et al., “Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets,” Journal of Clinical Investigation, vol. 110, no. 6, pp. 851–860, 2002. [45] Y. Tanaka, P. O. T. Tran, J. Harmon, and R. P. Robertson, “A role for glutathione peroxidase in protecting pancreatic β cells against oxidative stress in a model of glucose toxicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 19, pp. 12363–12368, 2002. [46] S. Pelengaris, M. Khan, and G. I. Evan, “Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression,” Cell, vol. 109, no. 3, pp. 321–334, 2002. [47] D.R. Laybutt,G.C.Weir, H. Kaneto et al., “Overexpression of c-Myc in β-cells of transgenic mice causes proliferation and apoptosis, downregulation of insulin gene expression, and diabetes,” Diabetes, vol. 51, no. 6, pp. 1793–1804, 2002. [48] S. Pelengaris and M. Khan, “The many faces of c-MYC,” Archives of Biochemistry and Biophysics, vol. 416, no. 2, pp. 129–136, 2003. [49] N. Kaiser, G. Leibowitz, and R. Nesher, “Glucotoxicity and β-cell failure in type 2 diabetes mellitus,” Journal of Pediatric Endocrinology and Metabolism, vol. 16, no. 1, pp. 5–22, 2003. [50] A. Clark, C. A. Wells, I. D. Buley et al., “Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes,” Diabetes Research, vol. 9, no. 4, pp. 151–159, 1988. [51] G. Kl¨oppel, M. L¨ohr, K. Habich, M. Oberholzer, and P. U. Heitz, “Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited,” Survey and Synthesis of Pathology Research, vol. 4, no. 2, pp. 110–125, 1985. [52] H. Sakuraba,H.Mizukami, N. Yagihashi, R.Wada, C.Hanyu, and S. Yagihashi, “Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients,” Diabetologia, vol. 45, no. 1, pp. 85– 96, 2002. [53] K. H. Yoon, S. H. Ko, J. H. Cho et al., “Selective β-cell loss and α-cell expansion in patients with type 2 diabetes mellitus in Korea,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 5, pp. 2300–2308, 2003. [54] A. Andersson, “The influence of hyperglycaemia, hyperinsulinaemia and genetic background on the fate of intrasplenically implanted mouse islets,” Diabetologia, vol. 25, no. 3, pp. 269–272, 1983. [55] C. Guillen, P. Navarro, M. Robledo, A. M. Valverde, and M. Benito, “Differential mitogenic signaling in insulin receptordeficient fetal pancreatic β-cells,” Endocrinology, vol. 147, no. 4, pp. 1959–1968, 2006. [56] T. R. Koiter, S. Wijkstra, G. C. J. van der Schaaf-Verdonk, H. Moes, and G. A. Schuiling, “Pancreatic beta-cell function and islet-cell proliferation: effect of hyperinsulinaemia,” Physiology and Behavior, vol. 57, no. 4, pp. 717–721, 1995. [57] J.Movassat, C. Saulnier, and B. Portha, “β-cellmass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent diabetes mellitus,” Diabete et Metabolisme, vol. 21, no. 5, pp. 365–370, 1995. [58] Y. Guz, I. Nasir, and G. Teitelman, “Regeneration of pancreatic β cells from intra-islet precursor cells in an experimental model of diabetes,” Endocrinology, vol. 142, no. 11, pp. 4956– 4968, 2001. [59] K. Otani, R. N. Kulkarni, A. C. Baldwin et al., “Reduced β- cell mass and altered glucose sensing impair insulin-secretory function in βIRKOmice,” American Journal of Physiology, vol. 286, no. 1, pp. E41–E49, 2004. [60] N. Blume, J. Skouv, L. I. Larsson, J. J. Hoist, and O. D. Madsen, “Potent inhibitory effects of transplantable rat glucagonomas and insulinomas on the respective endogenous islet cells are associated with pancreatic apoptosis,” Jour-nal of Clinical Investigation, vol. 96, no. 5, pp. 2227– 2235, 1995. [61] P. R. Flatt, K. S. Tan, and C. J. Bailey, “Effects of transplantation and resection of a radiation-induced rat insulinoma on glucose homeostasis and the endocrine pancreas,” British Journal of Cancer, vol. 54, no. 4, pp. 685–692, 1986. [62] S. N. Flier, R. N. Kulkarni, and C. R. Kahn, “Evidence for a circulating islet cell growth factor in insulin-resistant states,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 13, pp. 7475–7480, 2001. [63] C. Miyaura, L. Chen, M. Appel et al., “Expression of reg/PSP, a pancreatic exocrine gene: relationship to changes in islet β- cell mass,” Molecular Endocrinology, vol. 5, no. 2, pp. 226– 234, 1991. [64] A. Giacca, C. Xiao, A. I. Oprescu, A. C. Carpentier, and G. F. Lewis, “Lipid-induced pancreatic β-cell dysfunction: focus on in vivo studies,” American Journal of Physiology, vol. 300, no. 2, pp. E255–E262, 2011. [65] V. Poitout, “Glucolipotoxicity of the pancreatic β-cell: myth or reality?” Biochemical Society Transactions, vol. 36, no. 5, pp. 901–904, 2008. [66] Y. P. Zhou and V. E. Grill, “Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle,” Journal of Clinical Investigation, vol. 93, no. 2, pp. 870– 876, 1994. [67] Y. P. Zhou and V. Grill, “Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 5, pp. 1584–1590, 1995. [68] A. I. Oprescu, G. Bikopoulos, A. Naassan et al., “Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo,” Diabetes, vol. 56, no. 12, pp. 2927–2937, 2007. [69] A. Carpentier, S. D. Mittelman, R. N. Bergman, A. Giacca, and G. F. Lewis, “Prolonged elevation of plasma free fatty acids impairs pancreatic β- cell function in obese nondiabetic humans but not in individuals with type 2,” Diabetes, vol. 49, no. 3, pp. 399–408, 2000. [70] A. Carpentier, S. D.Mittelman, B. Lamarche, R. N. Bergman, A. Giacca, and G. F. Lewis, “Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation,” American Journal of Physiology, vol. 276, no. 6, pp. E1055–E1066, 1999. [71] S. Kashyap, R. Belfort, A. Gastaldelli et al., “A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes,” Diabetes, vol. 52, no. 10, pp. 2461–2474, 2003. [72] C. Xiao, A. Giacca, A. Carpentier, and G. F. Lewis, “Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, nondiabetic humans,” Diabetologia, vol. 49, no. 6, pp. 1371–1379, 2006.
URI:	http://wrap.warwick.ac.uk/id/eprint/45606

Request changes to a record

Actions (login required)

View Item